Lalic N, et al. - This cost-utility analysis examined the cost-effectiveness of insulin degludec compared to insulin glargine U100 in patients with type 1 (T1DM) and type 2 diabetes mellitus (T2DM) in Serbia. Costs were estimated from the healthcare payer perspective, the Serbian Health Insurance Fund (RFZO). As per the data, insulin costs were higher with degludec than with glargine U100. Nevertheless, these costs were partially offset by savings from a lower daily insulin dose in T1DM and T2DM on basal oral therapy (T2DM_BOT). It was deduced that degludec was a cost-effective alternative to glargine U100 for patients with T1DM and T2DM in Serbia. Findings displayed that degludec could particularly benefit those suffering from hypoglycaemia or where the patient would benefit from the option of flexible dosing.